Portal de Periódicos da CAPES

Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF/ANRS CO22 Hepather cohort

2020; Elsevier BV; Volume: 45; Issue: 1 Linguagem: Inglês

10.1016/j.clinre.2020.04.022

2210-741X

Anaı̈s Vallet-Pichard, Jean‐Michel Correas, Céline Dorival, Fabien Zoulim, Albert Tran, Marc Bourlière, Paul Calès, Dominique Guyader, Jean‐Pierre Bronowicki, Dominique Larrey, Christophe Hézode, V. Loustaud‐Ratti, Jérôme Gournay, Victor de Lédinghen, Tarik Asselah, Nathalie Ganne‐Carrié, Sophie Métivier, Olivier Chazouillères, Vincent Leroy, Isabelle Rosa, Didier Samuel, Philippe Mathurin, Carole Cagnot, Hélène Fontaine, Fabrice Carrat, Stanislas Pol, Delphine Bonnet, Virginie Payssan-Sicart, Chloe Pomes, François Bailly, Marjolaine Beaudoin, Dominique Giboz, Kerstin Hartig-Lavie, M. Travis Maynard, Eric Billaud, D. Boutoille, Morane Cavellec, Marjorie Cheraud-Carpentier, Isabelle Hubert, Jaouad Benhida, Adrien Lannes, F. Lunel, F. Oberti, Nathalie Boyer, Nathalie Giuily, Corinne Castelnau, Giovanna Scoazec, Aziza Chibah, Sylvie Keser, Karim Bonardi, Anaı̈s Vallet-Pichard, Philippe Sogni, Juliette Foucher, Jean‐Baptiste Hiriart, Amy C. Wilson, Sarah Shili, Faïza Chermak, Christelle Ansaldi, Nisserine Ben Amara, Laëtitia Chouquet, Emilie De Luca, Valérie Oulès, Rodolphe Anty, Ève Gelsi, Régine Truchi, Elena Luckina, Nadia Messaoudi, Joseph Moussali, Barbara De Dieuleveult, Damien Labarrière, Pascal Poter, Si Nafa Si Ahmed, Véronique Grando–Lemaire, Pierre Nahon, Valérie Bourcier, Séverine Brulé, Thomas Stalhberger, Caroline Jézéquel, Audrey Brener, Anne Laligant, Aline Rabot, Isabelle Renard, Thomas F. Baumert, Michel Doffoël, Catherine Schmidt‐Mutter, Pauline Simo‐Noumbissie, Esma Razi, Hélène Barraud, Mouni Bensenane, Abdelbasset Nani, Sarah Hassani-Nani, Marie-Albertine Bernard, Georges‐Philippe Pageaux, Michaël Bismuth, Ludovic Caillo, Stéphanie Faure, Marie–Pierre Ripault, Christophe Bureau, Jean Marie Péron, Marie‐Angèle Robic, Léa Tarallo, Marine Faure, Bruno Froissart, Marie‐Noëlle Hilleret, Jean–Pierre Zarski, Odile Goria, Victorien Grard, Hélène Montialoux, Muriel François, Christian Ouedraogo, Christelle Pauleau, Anne Varault, Tony Andréani, Bénédicte Angoulevant, Azeline Chevance, Lawrence Serfaty, Térésa Antonini, Audrey Coilly, Jean‐Charles Duclos Vallée, Mariagrazia Tateo, Christophe Bonny, Chanteranne Brigitte, Géraldine Lamblin, Léon Muti, Abdenour Babouri, Virginie Filipe, Abdenour Babouri, Virginie Filipe, Camille Barrault, Laurent Costes, Hervé Hagège, Soraya Merbah, Paul Carrier, Maryline Debette‐Gratien, Jérémie Jacques, Guillaume Lassailly, Florent Artu, V. Canva, Sébastien Dharancy, Alexandre Louvet, Marianne Latournerie, Marc Bardou, Thomas Mouillot, Yannick Bacq, Didier Barbereau, Charlotte Nicolas, Caroline Chevalier, Isabelle Archambeaud, Sarah Habès, Nisserine Ben Amara, Danièle Botta-Fridlund, Eric Saillard, Marie-Josée Lafrance,

Liver Disease Diagnosis and Treatment

Although it has now been excluded that direct-acting antivirals (DAA) are associated with a significant risk of hepatocellular carcinoma (HCC) in HCV-infected patients, a possible effect of DAA on tumor growth is still a subject of debate. We performed a blind comparison of the kinetics of HCC recurrence in patients after HCV treatment with or without DAA to evaluate the potential aggressiveness of HCC after DAA treatment.Thirty-nine HCV-infected patients from the AFEF/ANRS CO22 Hepather cohort who experienced HCC recurrence after so-called curative treatment were evaluated. Contrast-enhanced CT and/or MR images were read blindly 6 months before HCC recurrence and during the follow-up period. Seventeen patients who received DAA (DAA+) before HCC recurrence were compared to the 22 who did not receive (DAA-), according to the LiRads and mRECIST criteria.There were 28 men and 11 women, median age 62 years old, 37 (95%) with cirrhosis. DAA+ patients had a lower median MELD score (8±2 vs. 10±4, P=0.0286) than DAA- patients. The median time to HCC recurrence (time from the date of curative treatment to the diagnosis of recurrence) was not different (20 vs. 18 months) (P=0.73) between the two groups. There was no difference between the 2 groups in the overall survival and/or transplantation-free survival (P=0.71) and for the mRECIST time to progression (P=0.25).This blinded analysis of HCC recurrence after HCC treatment does not support any negative impact of DAA therapy on the severity or progression of recurrent HCC.